Paclitaxel, bevacizumab, and everolimus/placebo as...

Breast Cancer Research and Treatment 2015 / 11 Vol. 154; Iss. 1

Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute

Yardley, Denise A., Bosserman, Linda D., O’Shaughnessy, Joyce A., Harwin, William N., Morgan, Susan K., Priego, Victor M., Peacock, Nancy W., Bass, J. David, Burris III, Howard A., Hainsworth, John D.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
154
Language:
english
Journal:
Breast Cancer Research and Treatment
DOI:
10.1007/s10549-015-3599-5
Date:
November, 2015
File:
PDF, 691 KB
english, 2015
Conversion to is in progress
Conversion to is failed